<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Health Newspapers — Mind</title>
    <link>https://www.healthnewspapers.com/mind</link>
    <description>Mental health, psychedelics, loneliness, and neuroscience.</description>
    <language>en-us</language>
    <atom:link href="https://www.healthnewspapers.com/mind/rss.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Postpartum depressive symptoms linked to higher infant mortality</title>
      <link>https://www.healthnewspapers.com/mind/perinatal-depression-infant-mortality-new-jersey</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/perinatal-depression-infant-mortality-new-jersey</guid>
      <description>In 415,000 New Jersey births, infants of mothers who screened positive for depression died before age one at more than three times the rate, an association steady across race, income and preterm birth.</description>
      <pubDate>Fri, 04 Sep 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Ketamine beat midazolam in treatment-resistant bipolar depression</title>
      <link>https://www.healthnewspapers.com/mind/serial-ketamine-treatment-resistant-bipolar-depression</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/serial-ketamine-treatment-resistant-bipolar-depression</guid>
      <description>In the Ket-BD trial, four IV ketamine infusions over two weeks lowered depression scores more than an active placebo, with no manic switches observed in 63 analysed patients.</description>
      <pubDate>Thu, 03 Sep 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Supplements for depression: big effect sizes the authors call unrealistic</title>
      <link>https://www.healthnewspapers.com/mind/nutraceuticals-depression-network-meta-analysis</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/nutraceuticals-depression-network-meta-analysis</guid>
      <description>A network meta-analysis of 163 trials found EPA, vitamin D and a St John&apos;s wort extract beat placebo by margins so large the researchers treat them as a warning about the evidence, not a green light.</description>
      <pubDate>Wed, 02 Sep 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Cannabis edibles impaired simulated driving below the legal blood limits</title>
      <link>https://www.healthnewspapers.com/mind/cannabis-edibles-simulated-driving</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/cannabis-edibles-simulated-driving</guid>
      <description>In a 40-person crossover trial, 10 mg and 20 mg of edible THC degraded lane-keeping while whole-blood THC peaked at 1.6 and 3.4 ng/mL — near or under the thresholds police enforce.</description>
      <pubDate>Mon, 31 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Screen use explained at most 0.4% of the variation in adolescent well-being</title>
      <link>https://www.healthnewspapers.com/mind/social-media-adolescent-wellbeing-effect-size</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/social-media-adolescent-wellbeing-effect-size</guid>
      <description>Two large re-analyses of the same public datasets found the association is real, negative and very small. A third review found the association is not even consistent between the Global North and South.</description>
      <pubDate>Sun, 30 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Clozapine&apos;s neutropenia risk is front-loaded. Twenty years of Hong Kong data show when.</title>
      <link>https://www.healthnewspapers.com/mind/clozapine-neutropenia-monitoring-hong-kong</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/clozapine-neutropenia-monitoring-hong-kong</guid>
      <description>In 4,868 clozapine users followed to 2023, excess neutropenia risk concentrated in the first 18 weeks and converged with other antipsychotics by around two years.</description>
      <pubDate>Sat, 29 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Open Dialogue missed its primary endpoint. It still cut inpatient admissions.</title>
      <link>https://www.healthnewspapers.com/mind/oddessi-open-dialogue-crisis-care</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/oddessi-open-dialogue-crisis-care</guid>
      <description>The ODDESSI trial ran in 30 clusters across five NHS trusts in England. Time to relapse was unchanged; inpatient admission, re-referral and service-user ratings all moved in Open Dialogue&apos;s favour.</description>
      <pubDate>Wed, 26 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>GLP-1 drugs, death rates and serious mental illness: a very large, very soft signal</title>
      <link>https://www.healthnewspapers.com/mind/glp1-mortality-serious-mental-illness</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/glp1-mortality-serious-mental-illness</guid>
      <description>A 1.5-million-person records study reports lower mortality with GLP-1 drugs than with SGLT2 inhibitors, and the largest absolute gains in people with serious mental illness. The design cannot prove it.</description>
      <pubDate>Wed, 26 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Court-documented child maltreatment did not register on two epigenetic clocks</title>
      <link>https://www.healthnewspapers.com/mind/childhood-maltreatment-epigenetic-clocks-null</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/childhood-maltreatment-epigenetic-clocks-null</guid>
      <description>In 276 adults tested at 60, the differences in GrimAge and DunedinPACE were small, their intervals crossed zero, and most of what was there disappeared once smoking was accounted for.</description>
      <pubDate>Tue, 25 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Stimulants beat behaviour therapy for ADHD at 14 months. By 8 years the gap was gone.</title>
      <link>https://www.healthnewspapers.com/mind/adhd-stimulant-treatment-children-evidence</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/adhd-stimulant-treatment-children-evidence</guid>
      <description>The MTA trial randomised 579 children and found medication management clearly superior short-term. Its own long-term follow-up found the treatment groups no longer differed by 6 to 8 years.</description>
      <pubDate>Tue, 25 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Rapamycin was undetectable in spinal fluid in the first trial that looked</title>
      <link>https://www.healthnewspapers.com/mind/rapamycin-brain-alzheimers-trials</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/rapamycin-brain-alzheimers-trials</guid>
      <description>A ten-person phase 1 study measured whether oral rapamycin reaches the central nervous system in early Alzheimer&apos;s. It did not — and several disease biomarkers rose over eight weeks.</description>
      <pubDate>Mon, 24 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Burnout is officially recognised — but not as a medical condition</title>
      <link>https://www.healthnewspapers.com/mind/burnout-condition-versus-metaphor-evidence</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/burnout-condition-versus-metaphor-evidence</guid>
      <description>WHO&apos;s ICD-11 lists burn-out, yet places it among reasons people contact health services, not among illnesses. It is defined strictly as a workplace phenomenon, which shapes who should be assessing it and how.</description>
      <pubDate>Mon, 24 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Anxiety cases rose 50% in three decades. The age-standardised rate did not move.</title>
      <link>https://www.healthnewspapers.com/mind/anxiety-cases-versus-rates-and-diagnosis</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/anxiety-cases-versus-rates-and-diagnosis</guid>
      <description>The Global Burden of Disease estimates for anxiety disorders separate two things that public debate keeps merging: how many people have it, and how likely a given person is to. Diagnosis is a third question again.</description>
      <pubDate>Mon, 24 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Largest single-site psilocybin brain-imaging study finds context shapes the response</title>
      <link>https://www.healthnewspapers.com/mind/psilocybin-context-brain-reorganization-nature</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/psilocybin-context-brain-reorganization-nature</guid>
      <description>In 62 adults scanned under psilocybin during rest, meditation, music, and film, brain networks reorganized differently by setting — and more reorganization tracked with more positive experiences.</description>
      <pubDate>Sun, 23 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Large German cohort finds data-driven evidence gut bacteria contribute to depression</title>
      <link>https://www.healthnewspapers.com/mind/gut-microbiota-causal-depression-study</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/gut-microbiota-causal-depression-study</guid>
      <description>Using causal-inference methods on 1,269 people, researchers linked two bacterial genera to depression independent of body weight and medication — the first such evidence in humans, not proof of mechanism.</description>
      <pubDate>Sun, 23 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Australia banned under-16s from social media. Measuring whether it worked is the hard part</title>
      <link>https://www.healthnewspapers.com/mind/australia-social-media-age-law-how-it-gets-measured</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/australia-social-media-age-law-how-it-gets-measured</guid>
      <description>A 422-family cohort with a pre-ban baseline is the closest thing to a controlled test the world has. Researchers are also warning the law will make studying adolescents harder — including studying this.</description>
      <pubDate>Sat, 22 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Sleep training works short-term, and the follow-up trials find no lasting harm</title>
      <link>https://www.healthnewspapers.com/mind/sleep-training-evidence-long-term</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/sleep-training-evidence-long-term</guid>
      <description>A randomised trial tracked infants&apos; cortisol and attachment; a five-year follow-up tracked mental health. Graduated extinction improved sleep with no sign of long-term damage — or lasting benefit.</description>
      <pubDate>Wed, 19 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Eight weeks of mindfulness matched a first-line anxiety drug in a randomised trial</title>
      <link>https://www.healthnewspapers.com/mind/mbsr-versus-escitalopram-anxiety-trial</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/mbsr-versus-escitalopram-anxiety-trial</guid>
      <description>The TAME trial randomised 276 adults with diagnosed anxiety disorders to mindfulness-based stress reduction or escitalopram. The difference on the primary measure was 0.07 points, inside the noninferiority margin.</description>
      <pubDate>Wed, 19 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Cognitive reserve is real. What you can do about it is a smaller, honest list.</title>
      <link>https://www.healthnewspapers.com/mind/cognitive-reserve-real-but-hard-to-build</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/cognitive-reserve-real-but-hard-to-build</guid>
      <description>Autopsy studies show educated brains carry the same disease but express it as dementia later. That is the concept&apos;s strength — and the reason it resists being turned into a to-do list.</description>
      <pubDate>Tue, 18 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>A psychedelic could win FDA approval within months. None ever has.</title>
      <link>https://www.healthnewspapers.com/mind/psilocybin-fda-priority-review</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/psilocybin-fda-priority-review</guid>
      <description>The agency compressed review of three psychedelic therapies from a year to weeks. A first approval decision is plausible by early 2027.</description>
      <pubDate>Fri, 14 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Exercise is sold as brain insurance. The trial evidence is weaker than the headlines.</title>
      <link>https://www.healthnewspapers.com/mind/exercise-aging-brain-trial-evidence</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/exercise-aging-brain-trial-evidence</guid>
      <description>Observational studies tie fitness to slower cognitive decline. When researchers randomise older adults to exercise, the cognitive payoff shrinks — in a Cochrane review of healthy people, to nothing.</description>
      <pubDate>Fri, 14 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Most kinds of therapy for depression worked. Almost none outperformed another.</title>
      <link>https://www.healthnewspapers.com/mind/which-psychotherapy-for-depression-evidence</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/which-psychotherapy-for-depression-evidence</guid>
      <description>A network meta-analysis of 331 trials and 34,285 adults found no significant differences between the main psychotherapies, with one exception. In children and adolescents the picture is narrower.</description>
      <pubDate>Wed, 12 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Crossword-doers decline more slowly. That is not the same as crosswords working.</title>
      <link>https://www.healthnewspapers.com/mind/crosswords-reverse-causation-cognitive-decline</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/crosswords-reverse-causation-cognitive-decline</guid>
      <description>The link between puzzles and a sharper old age is real in the data and largely the wrong way round: the earliest changes of dementia quietly reduce the very activities that later look protective.</description>
      <pubDate>Tue, 11 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Brain-training games reliably improve one thing: your score on that game</title>
      <link>https://www.healthnewspapers.com/mind/brain-training-games-transfer-active-trial</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/brain-training-games-transfer-active-trial</guid>
      <description>The best long-term trial found trained skills can last a decade. Whether they transfer to daily life, or hold off dementia, is where the evidence — and the FTC — parted ways with the marketing.</description>
      <pubDate>Fri, 07 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Therapy and antidepressants performed equally. Together they beat either alone.</title>
      <link>https://www.healthnewspapers.com/mind/therapy-versus-antidepressants-network-meta-analysis</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/therapy-versus-antidepressants-network-meta-analysis</guid>
      <description>A network meta-analysis of 101 trials and 11,910 patients found no significant difference between psychotherapy and medication for adult depression — and a consistent advantage for combining them.</description>
      <pubDate>Wed, 05 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Nociplastic pain is not central sensitisation, and the difference is not pedantry</title>
      <link>https://www.healthnewspapers.com/mind/nociplastic-pain-central-sensitisation-concept</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/nociplastic-pain-central-sensitisation-concept</guid>
      <description>Pain medicine added a third mechanistic category in 2017 and has been arguing about it since. There is no test for it, the criteria work by exclusion, and the experts who wrote them say that is a problem.</description>
      <pubDate>Wed, 05 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>The Lancet&apos;s 45% dementia figure is a population estimate, not a personal promise</title>
      <link>https://www.healthnewspapers.com/mind/lancet-commission-45-percent-dementia-what-it-means</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/lancet-commission-45-percent-dementia-what-it-means</guid>
      <description>A standing commission estimates that eliminating 14 risk factors could prevent or delay 45% of dementia across a whole population. What that number means for one person is a different and much weaker claim.</description>
      <pubDate>Tue, 04 Aug 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Severe mental illness in Europe: 2.6 times the death rate, mostly physical disease</title>
      <link>https://www.healthnewspapers.com/mind/severe-mental-illness-physical-mortality-gap-europe</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/severe-mental-illness-physical-mortality-gap-europe</guid>
      <description>A registry study spanning 4.9 million people separates where the most deaths occur from where the inequality is largest. Heart disease and lung disease give different answers.</description>
      <pubDate>Tue, 28 Jul 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Half the mental health apps proven in trials cannot be downloaded</title>
      <link>https://www.healthnewspapers.com/mind/mental-health-apps-evidence-availability-gap</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/mental-health-apps-evidence-availability-gap</guid>
      <description>A review of 110 studies found that 52% of trialled self-guided apps were publicly available — and that evidence quality had no bearing on which ones made it to an app store.</description>
      <pubDate>Fri, 24 Jul 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Semaglutide and tirzepatide cut alcohol-related hospitalizations by up to 65%</title>
      <link>https://www.healthnewspapers.com/mind/glp1-alcohol-related-hospitalizations-target-trial</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/glp1-alcohol-related-hospitalizations-target-trial</guid>
      <description>Four separate trial emulations, each with a different comparator, all pointed the same direction. The strongest effect appeared among people being treated for alcohol use disorder.</description>
      <pubDate>Fri, 24 Jul 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>From rodent cages to Medicare claims: GLP-1 drugs and opioid use disorder</title>
      <link>https://www.healthnewspapers.com/mind/glp1-opioid-use-disorder-rats-to-humans-review</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/glp1-opioid-use-disorder-rats-to-humans-review</guid>
      <description>A review lays out the evidence chain: animal studies showing reduced drug-seeking, one small human trial, and record-based analyses linking GLP-1 prescriptions to 40% fewer opioid overdoses.</description>
      <pubDate>Wed, 22 Jul 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Measurement-based care works in trials. Twenty-four years on, it still rarely lands</title>
      <link>https://www.healthnewspapers.com/mind/measurement-based-care-implementation-gap</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/measurement-based-care-implementation-gap</guid>
      <description>A systematic review found only 16 usable studies of how to implement routine symptom monitoring in adult mental health services. A 4,778-patient clinic dataset shows what it looks like when it does.</description>
      <pubDate>Tue, 21 Jul 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Six months after a repeat ketamine course, only 17% still counted as responders</title>
      <link>https://www.healthnewspapers.com/mind/repeat-subcutaneous-ketamine-treatment-resistant-depression-kads</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/repeat-subcutaneous-ketamine-treatment-resistant-depression-kads</guid>
      <description>The KADS extension followed 130 patients who had already been through a ketamine trial. Response fell from 30% at treatment&apos;s end to 17% a month later.</description>
      <pubDate>Tue, 07 Jul 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>One ketamine infusion cut suicidal symptoms within a day, a 26-trial pooling finds</title>
      <link>https://www.healthnewspapers.com/mind/ketamine-suicidal-depressive-symptoms-meta-analysis</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/ketamine-suicidal-depressive-symptoms-meta-analysis</guid>
      <description>The meta-analysis behind ketamine&apos;s widening off-label use for suicidal crisis quantifies what 1,166 patients across two decades of trials actually showed — and where the evidence runs out.</description>
      <pubDate>Thu, 02 Jul 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Across 18 countries, loneliness predicted decline and death. Being alone did not.</title>
      <link>https://www.healthnewspapers.com/mind/loneliness-not-isolation-cognition-mortality</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/loneliness-not-isolation-cognition-mortality</guid>
      <description>A registered report fit identical models to 11 longitudinal studies covering 175,070 people. The subjective feeling carried the signal; the objective count of social contacts largely did not.</description>
      <pubDate>Tue, 30 Jun 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Korea tightened its involuntary commitment rules in 2017. Emergency visits then rose.</title>
      <link>https://www.healthnewspapers.com/mind/korea-mental-health-act-emergency-visits</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/korea-mental-health-act-emergency-visits</guid>
      <description>A quasi-experimental analysis of 23 hospitals finds about 95 additional self-harm and suicide-related emergency visits a month after the law changed, alongside fewer psychiatric admissions.</description>
      <pubDate>Thu, 25 Jun 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Traffic noise may account for half a million European depression cases a year</title>
      <link>https://www.healthnewspapers.com/mind/transportation-noise-depression-dementia-burden-europe</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/transportation-noise-depression-dementia-burden-europe</guid>
      <description>A burden-of-disease calculation built on EU noise-mapping data puts numbers on two outcomes that noise research has mostly ignored. The confidence intervals are as informative as the estimates.</description>
      <pubDate>Wed, 24 Jun 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>At-home ketamine&apos;s entire evidence base came from the companies selling it</title>
      <link>https://www.healthnewspapers.com/mind/direct-to-consumer-ketamine-evidence-base</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/direct-to-consumer-ketamine-evidence-base</guid>
      <description>A systematic review screened 3,857 records and found three eligible studies, every one produced by a US commercial provider and every one at critical risk of bias.</description>
      <pubDate>Fri, 19 Jun 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>The hallucinogen-psychosis link mostly vanished after adjusting for prior illness</title>
      <link>https://www.healthnewspapers.com/mind/hallucinogen-psychosis-confounded-baseline-psychiatric-history</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/hallucinogen-psychosis-confounded-baseline-psychiatric-history</guid>
      <description>In 273,466 people with substance-related hospital admissions, psychosis was far more common after hallucinogen admissions, until adjustment for preexisting conditions erased the link.</description>
      <pubDate>Mon, 15 Jun 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>In veterans, psilocybin&apos;s anxiety relief tracked entirely with depression improvement</title>
      <link>https://www.healthnewspapers.com/mind/psilocybin-veterans-anxiety-quality-of-life</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/psilocybin-veterans-anxiety-quality-of-life</guid>
      <description>Anxiety, quality of life and PTSD symptoms all improved after a single dose in this 15-person trial. Once researchers accounted for depression improvement, those effects mostly disappeared.</description>
      <pubDate>Tue, 09 Jun 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Outside trials, psilocybin&apos;s real-world depression response rate ran lower</title>
      <link>https://www.healthnewspapers.com/mind/real-world-psilocybin-therapy-switzerland-trd</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/real-world-psilocybin-therapy-switzerland-trd</guid>
      <description>Switzerland allows limited psilocybin use for treatment-resistant depression. A review of 19 patients found meaningful improvement, but remission in barely a fifth to a quarter.</description>
      <pubDate>Wed, 03 Jun 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Psychedelics triggered mania in up to 30% of naturalistic bipolar cases, rarely in trials</title>
      <link>https://www.healthnewspapers.com/mind/psychedelic-induced-hypomania-mania-meta-analysis</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/psychedelic-induced-hypomania-mania-meta-analysis</guid>
      <description>A review pooling 23 studies found risk concentrated among people with bipolar I disorder, family history, or unsupervised use. About 4% later transitioned to bipolar disorder.</description>
      <pubDate>Sat, 30 May 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Intellectual disability fell across South America. Autism diagnoses barely moved.</title>
      <link>https://www.healthnewspapers.com/mind/neurodevelopmental-disorders-south-america-thirty-year-trends</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/neurodevelopmental-disorders-south-america-thirty-year-trends</guid>
      <description>A single-author analysis of Global Burden of Disease estimates finds the region&apos;s neurodevelopmental picture split in two — and argues the flat autism curve reflects diagnostic capacity, not risk.</description>
      <pubDate>Fri, 22 May 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>One psilocybin dose eased chronic suicidal ideation for 12 weeks, in 20 patients</title>
      <link>https://www.healthnewspapers.com/mind/psilocybin-chronic-suicidal-ideation-open-label</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/psilocybin-chronic-suicidal-ideation-open-label</guid>
      <description>By the study&apos;s end, 70% had scores low enough to be considered near-resolution. There was no placebo arm — every participant knew what they&apos;d received.</description>
      <pubDate>Tue, 19 May 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>The largest psilocybin depression trial yet missed its primary endpoint</title>
      <link>https://www.healthnewspapers.com/mind/episode-psilocybin-treatment-resistant-depression-trial</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/episode-psilocybin-treatment-resistant-depression-trial</guid>
      <description>EPISODE randomized 144 people with treatment-resistant depression across four arms. High-dose psilocybin missed its main outcome, even as secondary measures showed symptom benefit.</description>
      <pubDate>Sat, 16 May 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>In 40 people with cocaine use disorder, psilocybin nearly doubled abstinence odds</title>
      <link>https://www.healthnewspapers.com/mind/psilocybin-cocaine-use-disorder-trial</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/psilocybin-cocaine-use-disorder-trial</guid>
      <description>No medication has proven effective for cocaine use disorder. A single psilocybin dose, paired with therapy, produced more abstinent days and a longer time to relapse than an active placebo.</description>
      <pubDate>Sat, 09 May 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>Psilocybin eased depression within two days, but the placebo gap closed by one year</title>
      <link>https://www.healthnewspapers.com/mind/psilocybin-major-depression-rapid-effects-trial</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/psilocybin-major-depression-rapid-effects-trial</guid>
      <description>In 35 patients with recurrent major depression, psilocybin beat an active placebo through day 42. On self-reported measures the effect lingered further, but the trial&apos;s primary endpoint showed no difference at 365 days.</description>
      <pubDate>Wed, 06 May 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>A methylone drug eased PTSD in phase 2, without MDMA trials&apos; long therapy sessions</title>
      <link>https://www.healthnewspapers.com/mind/tsnd-201-methylone-ptsd-phase2-trial</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/tsnd-201-methylone-ptsd-phase2-trial</guid>
      <description>TSND-201 improved PTSD severity, disability, and depression scores over placebo in 65 participants — delivered as an oral dose with monitoring but no formal psychotherapy alongside it.</description>
      <pubDate>Sat, 02 May 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>2C-B produced MDMA-like and psilocybin-like effects in a head-to-head comparison</title>
      <link>https://www.healthnewspapers.com/mind/2cb-mdma-psilocybin-comparison-trial</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/2cb-mdma-psilocybin-comparison-trial</guid>
      <description>Twenty-four healthy volunteers received all three drugs in a crossover trial. At 30 mg, 2C-B matched MDMA&apos;s intensity and produced psilocybin-like states, without psilocybin&apos;s anxiety.</description>
      <pubDate>Thu, 30 Apr 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
    <item>
      <title>An estimated 8 million Americans used psilocybin in the past year</title>
      <link>https://www.healthnewspapers.com/mind/psilocybin-past-year-prevalence-us</link>
      <guid isPermaLink="true">https://www.healthnewspapers.com/mind/psilocybin-past-year-prevalence-us</guid>
      <description>The first federal survey to ask about psilocybin specifically finds 2.8% past-year use, concentrated among young, white, college-educated men. People with recent depression had 37% higher odds.</description>
      <pubDate>Thu, 23 Apr 2026 00:00:00 GMT</pubDate>
      <category>mind</category>
    </item>
  </channel>
</rss>